Reactivity of N terminal Histidine of Peptides towards Excipients/Impurity of Excipients: A Case Study of Liraglutide Excipient Compatibility Study.
肽類中N端組氨酸對輔料/輔料雜質的反應性:Liraglutide 輔料相容性研究的案例研究。
J Pharm Sci 2024-08-23
FRAP analysis of peptide diffusion in extracellular matrix mimetic hydrogels as an in vitro model for subcutaneous injection.
FRAP 分析在細胞外基質模擬水凝膠中肽擴散的應用,作為皮下注射的體外模型。
Int J Pharm 2024-08-23
The efficacy and safety of GLP-1 agonists in PCOS women living with obesity in promoting weight loss and hormonal regulation: A meta-analysis of randomized controlled trials.
GLP-1 受體激動劑在肥胖多囊卵巢症候群女性中促進減重和荷爾蒙調節的療效與安全性:隨機對照試驗的統合分析。
J Diabetes Complications 2024-08-23
Comparative renal outcomes of matched cohorts of patients with type 2 diabetes receiving SGLT2 inhibitors or GLP-1 receptor agonists under routine care.
接受常規護理的2型糖尿病患者中,使用SGLT2抑制劑或GLP-1受體激動劑的匹配隊列比較腎臟結果。
Diabetologia 2024-08-23
Food temperature altered macronutrients induced changes in satiety hormones; glucagon - like peptide -1 and cholecystokinin and their correlation with subjective satiety.
食物溫度改變了宏量營養素引起的飽腹激素變化;胰高血糖素樣肽-1和膽囊收縮素及其與主觀飽腹感的相關性。
J Family Community Med 2024-08-23
Reversible bilateral central scotoma under scotopic conditions associated with oral semaglutide.
與口服 semaglutide 相關的可逆性雙側中央暗點在暗視條件下的表現。
Am J Ophthalmol Case Rep 2024-08-23
Dietary intake by patients taking GLP-1 and dual GIP/GLP-1 receptor agonists: A narrative review and discussion of research needs.
服用 GLP-1 和雙重 GIP/GLP-1 受體激動劑患者的飲食攝取:敘述性回顧及研究需求討論。
Obes Pillars 2024-08-23
Patient and public involvement and engagement in the ASCEND PLUS trial: reflections from the design of a streamlined and decentralised clinical trial.
ASCEND PLUS 試驗中的病人及公眾參與與互動:對簡化及去中心化臨床試驗設計的反思。
Trials 2024-08-22
Cross-relationship between COVID-19 infection and anti-obesity products efficacy and incidence of side effects: A cross-sectional study.
COVID-19 感染與抗肥胖產品療效及副作用發生率之交叉關係:一項橫斷面研究。
PLoS One 2024-08-22